Skip to main content
OpenTrials

Clinical trial condition

Anemia, Refractory

Explore clinical trials studying Anemia, Refractory. Study availability and eligibility vary by location and protocol.

193 public trials 36 recruiting studies
Refine in advanced search Browse all conditions

Anemia, Refractory trial results

Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

NCT01174108

Conditions
Anemia, Anemia, Aplastic, Anemia, Hemolytic, +11 more
Locations
  • University of Maryland, Baltimore (UMB) Baltimore, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
View Trial Details
Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT00801489

Conditions
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, +19 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Luspatercept + Darbepoetin in MDS

NCT07096297

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +5 more
Locations
  • Yale University New Haven, Connecticut, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois, United States
  • Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Dallas, Texas, United States
  • The Ohio State University - The James Cancer Hospital and Solove Research Institute: Comprehensive Cancer Center ( Columbus, Ohio, United States
View Trial Details
Recruiting

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

NCT07025824

Conditions
AML - Acute Myeloid Leukemia, Anemia, Anemia, Refractory, +11 more
Locations
  • Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I Dresden, Germany
  • Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum Münster, Germany
  • Universitätsklinikum Aachen, Medizinische Klinik IV Aachen, Germany
  • Klinikum Augsburg, Medizinische Klinik II Augsburg, Germany
View all 17 locations
View Trial Details
Recruiting

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07249346

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +16 more
Locations
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • The University of Alabama at Birmingham Birmingham, Alabama, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View Trial Details
Recruiting

Personalized NK Cell Therapy in CBT

NCT02727803

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, +55 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions